Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Shares of Halozyme Therapeutics (HALO) and Jonhson & Johnson (JNJ) are under pressure on Tuesday after Leerink downgraded the stocks to Underperform and Market Perform, respectively. This comes after ...

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look ...

Halozyme’s recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks. Find out why HALO stock is a buy.

Despite Halozyme reporting generally positive first-quarter results, the stock was negatively impacted by the potential risk that its hyaluronidase combination products may face earlier price ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for oncology indications by targeting tumor ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by Leerink Partners, and Halozyme Therapeutics downgraded their underperform rating. The last upgrade for Halozyme ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...